Abstract Library

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#3361 FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

Introduction: Well-differentiated neuroendocrine tumors (NETs) are relatively rare, highly vascularized neoplasms. Antiangiogenic drugs have shown efficacy in patients with advanced NETs. Bevacizumab is a well-known antiangiogenic monoclonal antibody.

Conference:

Presenting Author:

Authors: Lacombe C, Perrier M, Hentic O, Brixi H, Rebours V,

Keywords: neuroendocrine tumor, antiangiogenic therapy, VEGF, well-differentiated,

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#2874 Role of FOXM1 in Aggressive Pancreatic / Pulmonary Neuroendocrine Carcinomas and Anti-Tumor Effect of the FOXM1 Inhibitor Thiostrepton

Introduction: DNA-targeting agents are the main treatment of aggressive pulmonary and pancreatic neuroendocrine carcinomas (NEC). FOXM1 is a transcription factor controlling cell proliferation and DNA repair pathways, playing therefore an important role in tumor progression and chemoresistance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: De Rycke O, Raffenne J, Lacombe C, Hentic O, Gounant V,

Keywords: neuroendocrine carcinoma, FOXM1, DNA repair, anti-tumor drug,

#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?

Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,

Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,